As anticipated, human donor-derived GPC2-directed CAR T cells demonstrated significant antigen-specific tumor cell killing relative to negative control donor-matched CD19 CAR T cells, untransduced T cells or target cells alone (Fig. 2C). This evidence concerns the gene CD19 and neoplasm.